The race for approvals in prostate cancer has intensified over the past year among the second-generation hormonal agents, Johnson and...
Read More...
The post What does NICE’s rejection of Xtandi mean for patients with nmCRPC? appeared first on Pharmaceutical Technology.
Original Article: What does NICE’s rejection of Xtandi mean for patients with nmCRPC?